{
    "url_original": "https://www.wsj.com/articles/biotech-startups-gain-leverage-as-ipos-spacs-beckon-11614249001?mod=markets_major_pos11",
    "url": "biotech-startups-gain-leverage-as-ipos-spacs-beckon-11614249001",
    "title": "Biotech Startups Gain Leverage as IPOs, SPACs Beckon",
    "sub_head": "As public markets sizzle and more routes to them emerge, entrepreneurs can carefully weigh their options",
    "time": "2021-02-25 05:30:00",
    "body": "Biotechnology startups can increasingly go public on their own terms as investors and blank-check companies clamor for access to the hottest new drugmakers.<br />Last year, 65 venture-backed biotechs held initial public offerings in the U.S., raising $11.4 billion, more than double the $4.9 billion they collected through 41 IPOs in 2019, according to PitchBook Data Inc.<br />This..."
}